Contact
searchSearch
HMP Global
Login

Substance Use Disorder Topic Center

a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
A person sits holding a pill in one hand and a glass of water in the other
News
Most US Residents Unaware PCPs Can Prescribe Medication for Opioid Use Disorder
08/19/2024
Jolynn Tumolo
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents...
08/19/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Buprenorphine an Effective Treatment for OUD With Fentanyl Use
08/09/2024
Brionna Mendoza
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether...
08/09/2024
Psych Congress Network
lab work
News
Dosing Starts in Pharmacokinetics Study of AD04 for Alcohol Use Disorder
07/08/2024
Jolynn Tumolo
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of...
07/08/2024
Psych Congress Network
What is best approach for interviewing patients with AUD on past habits?
Quiz
What is best approach for interviewing patients with AUD on past habits?
06/03/2024
Test your knowledge on APA guidelines
Test your knowledge on APA guidelines
Test your knowledge on APA...
06/03/2024
Psych Congress Network

More News & Updates

a person breaks a cigarette in half
News
GLP-1 Agonists Show Promise in Treating Alcohol and Substance Use Disorders
11/13/2025
Brionna Mendoza
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the...
11/13/2025
Psych Congress Network
woman surrounded by spilled pills
News
Heart Rate Variability Biofeedback May Reduce Craving and Substance Use During SUD Recovery
10/09/2025
Maria Mantas
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate...
10/09/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
a cartoon illustration of a man sitting on the floor with this hand on his head, looking distressed.
News
More Than a Fifth of Overdose Decedents Had Non–Substance Mental Health Disorder
09/23/2024
Jolynn Tumolo
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths...
09/23/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
A person sits holding a pill in one hand and a glass of water in the other
News
Most US Residents Unaware PCPs Can Prescribe Medication for Opioid Use Disorder
08/19/2024
Jolynn Tumolo
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents in a national survey did not know primary care physicians (PCPs) could prescribe medications for people with opioid use disorder (OUD) or believed incorrectly that they could not, according to a study findings...
Three-quarters of US residents...
08/19/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Buprenorphine an Effective Treatment for OUD With Fentanyl Use
08/09/2024
Brionna Mendoza
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.
Buprenorphine, whether...
08/09/2024
Psych Congress Network
lab work
News
Dosing Starts in Pharmacokinetics Study of AD04 for Alcohol Use Disorder
07/08/2024
Jolynn Tumolo
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of...
07/08/2024
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
An illustration of a brain
News
Disease Duration, Antipsychotic Use, and Brain Aging in Schizophrenia
01/06/2026
Sarah Fleming
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in...
01/06/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use